Peptide Powder Melanotan-2 Melanotan II

Melanotan II erfordert eine kumulative Dosierung, um wirksam zu sein. Abhängig von der Person, Die benötigte kumulative Dosis wird typischerweise von sein 10 zu 40 mg, wobei gerechtere Personen in der Regel Beträge am oberen Ende der Spanne benötigen. Abhängig von der benötigten Gesamtmenge und der für den Einzelnen geeigneten Tagesdosierung, MT-II-Injektionen müssen mindestens eine Woche vor einer verbesserten Bräunung begonnen werden. Typischer, MT-II use should begin at least a month prior to such need.Melanotan II can also be used on a cycled basis to maintain improved ability to tan.Further, Melanotan II kann gelegentlich zur prosexuellen Wirkung eingesetzt werden.

Melanotan-1, the precusor to Melanotan II, would eventually be licensed for commercialization as a tanning agent and has been in development for use as a potential “therapeutic tan,” with minimal need for prolonged sun exposure. In the initial clinical testing of Melanotan II, an immediate and unexpected response was noted. The main subject experienced an erection shortly after administration. It was suggested that Melanotan II “may prove equally effective in women” as a “treatment of female sexual dysfunction. At least one study has observed that administration of Melanotan II may increase sexual desire, which should warrant further “investigation of centrally acting agents on disorders of sexual desire.
Theoretically, Melanotan II may enhance sexual function in males (erectile activity) and females (increased levels of sexual desire and genital arousal). Unlike other sexual-enhancement drugs, it is hypothesizedd that Melanotan II works at a neurological level, eliciting a more “natural” sexual response with minimal side effects. It was suggested that Melanotan II “may prove equally effective in women” as a “treatment of female sexual dysfunction.[5] At least one study has observed that administration of Melanotan II may increase sexual desire, which should warrant further “investigation of centrally acting agents on disorders of sexual desire.